Akebia Therapeutics, Inc.
NASDAQ:AKBA
1.46 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 194.623 | 292.602 | 213.578 | 295.307 | 335.001 | 207.742 | 177.984 | 1.535 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 75.734 | 84.796 | 153.394 | 295.908 | 145.336 | 7.685 | 0.617 | 115.785 | 0.096 | 23.263 | 0 | 0 |
| Gross Profit
| 118.889 | 207.806 | 60.184 | -0.601 | 189.665 | 200.057 | 177.367 | -114.25 | -0.096 | -23.263 | 0 | 0 |
| Gross Profit Ratio
| 0.611 | 0.71 | 0.282 | -0.002 | 0.566 | 0.963 | 0.997 | -74.43 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 61.494 | 129.114 | 147.852 | 218.485 | 322.969 | 291.068 | 230.893 | 115.785 | 43.016 | 25.398 | 10.782 | 5.632 |
| General & Administrative Expenses
| 3.237 | 141.874 | 177.65 | 157.356 | 152.984 | 87.128 | 27.008 | 22.21 | 18.497 | 12.542 | 5.152 | 2.891 |
| Selling & Marketing Expenses
| 100.233 | -3.175 | 174.161 | 153.947 | 149.455 | 87.061 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 103.47 | 141.874 | 174.161 | 153.947 | 149.455 | 87.061 | 27.008 | 22.21 | 18.497 | 12.542 | 5.152 | 2.891 |
| Other Expenses
| 0.887 | -12.541 | 3.489 | 3.409 | 3.529 | 6.235 | 0.204 | -0.188 | 0.287 | 0.7 | 1.05 | 1.971 |
| Operating Expenses
| 164.964 | 270.988 | 325.502 | 375.841 | 475.953 | 378.196 | 257.901 | 137.995 | 61.513 | 37.94 | 15.933 | 8.523 |
| Operating Income
| -46.075 | -63.182 | -265.318 | -376.442 | -286.288 | -178.139 | -79.917 | -136.46 | -61.513 | -37.94 | -15.933 | -8.523 |
| Operating Income Ratio
| -0.237 | -0.216 | -1.242 | -1.275 | -0.855 | -0.858 | -0.449 | -88.899 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -5.85 | -29.38 | -17.522 | -7.015 | -0.002 | 6.235 | 0.204 | -0.188 | 0.287 | 0.7 | 3.47 | 1.971 |
| Income Before Tax
| -51.925 | -92.562 | -282.84 | -383.457 | -286.29 | -171.904 | -76.914 | -135.747 | -60.716 | -37.034 | -13.167 | -8.196 |
| Income Before Tax Ratio
| -0.267 | -0.316 | -1.324 | -1.299 | -0.855 | -0.827 | -0.432 | -88.435 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 41.678 | 13.447 | -37.97 | -33.59 | -6.631 | -28.338 | -2.799 | -0.901 | -0.51 | -0.206 | 1.753 | 1.605 |
| Net Income
| -51.925 | -106.009 | -244.87 | -349.867 | -279.659 | -171.904 | -76.914 | -135.747 | -60.716 | -37.034 | -13.167 | -8.196 |
| Net Income Ratio
| -0.267 | -0.362 | -1.147 | -1.185 | -0.835 | -0.827 | -0.432 | -88.435 | 0 | 0 | 0 | 0 |
| EPS
| -0.28 | -0.58 | -1.48 | -2.53 | -2.36 | -1.47 | -1.77 | -3.6 | -2.29 | -2.4 | -0.68 | -0.81 |
| EPS Diluted
| -0.28 | -0.58 | -1.48 | -2.53 | -2.36 | -1.47 | -1.77 | -3.6 | -2.29 | -2.4 | -0.68 | -0.81 |
| EBITDA
| -4.229 | -46.343 | -265.318 | -376.442 | -286.288 | -178.139 | -79.3 | -136.164 | -61.417 | -37.891 | -14.882 | -8.523 |
| EBITDA Ratio
| -0.022 | -0.158 | -1.242 | -1.275 | -0.855 | -0.858 | -0.446 | -88.706 | 0 | 0 | 0 | 0 |